With this acquisition, Hikma Pharma expects to enhance its Injectables platform across the world.
Following the acquisition, Hikma will divest two West-Ward products, Phenytoin and Promethazine, as required by the US Federal Trade Commission.
Hikma CEO Said Darwazah said the acquisition of Baxter’s MSI business is transformational for Hikma.
"The acquisition doubles the size of our global Injectables business and doubles our sales in the US market, while further diversifying our global revenue base. I am delighted to welcome our new employees and customers to Hikma," Darwazah said .